REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms

FDA Approves Brexpiprazole for Agitation Associated with Alzheimer

Otsuka and Lundbeck Announce U.S. Food and Drug Administration

FDA Accepts sNDA for Rexulti for Alzheimer's Agitation

Ask the Pharmacist: New drug treats Alzheimer's agitation

Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication

JAMA Neurology Publishes Complete Results of Positive Phase 3

FDA approves first drug to treat agitation linked with Alzheimer's

Alarm as FDA fast-tracks first antipsychotic drug for agitation in

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation